Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Drug Safety
Published in: Drug Safety 2/2012

01-02-2012 | Editorial

Prevention and Pharmacovigilance

What Should We Do, What Can We Do?

Author: Professor I. Ralph Edwards

Published in: Drug Safety | Issue 2/2012

Login to get access

Excerpt

The last annual International Society of Pharmacovigilance (ISoP) meeting, held in Istanbul from 26–28 October 2011, was a well organized and run occasion with a potpourri of topics that must have provided something for everybody. They certainly allowed me many opportunities for thought after the meeting. I find it is often the way that, during and after a meeting, perhaps while walking around beautiful and interesting cities like Istanbul, I subconsciously connect lecture contents in a way that was probably not meant, and might not even be logical. …
Literature
1.
Mease M. Measuring REMS effectiveness: time for a program overhaul? [abstract]. Drug Saf 2011; 34(10): 887
2.
Waller PC, Evans SJ. A model for the future conduct of pharmacovigilance. Pharmacoepidemiol Drug Saf 2003 Jan–Feb; 12(1): 17–29PubMedCrossRef
3.
Ferner RE, Aronson JK. Preventability of drug-related harms —part I: a systematic review. Drug Saf 2010 Nov 1; 33(11): 985–94PubMedCrossRef
4.
Aronson JK, Ferner RE. Preventability of drug-related harms —part II: proposed criteria, based on frameworks that classify adverse drug reactions. Drug Saf 2010 Nov 1; 33(11): 995–1002PubMedCrossRef
Metadata
Title
Prevention and Pharmacovigilance
What Should We Do, What Can We Do?
Author
Professor I. Ralph Edwards
Publication date
01-02-2012
Publisher
Springer International Publishing
Published in
Drug Safety / Issue 2/2012
Print ISSN: 0114-5916
Electronic ISSN: 1179-1942
DOI
https://doi.org/10.2165/11630510-000000000-00000

Other articles of this Issue 2/2012

Drug Safety 2/2012 Go to the issue

Systematic Review

Effects of Proton Pump Inhibitors on Platelet Function in Patients Receiving Clopidogrel

Erratum

Erratum to Trends in hepatic injury associated with unintentional overdose of paracetamol (acetaminophen) in products with and without opioid: an analysis using the National Poison Data System of the American Association of Poison Control Centers, 2000–7

Leading Article

Risk Evaluation and Mitigation Strategies (REMS)

Short Communication

Selected National Pharmacovigilance Websites

Original Research Article

Risk of Cardiac Valve Regurgitation with Dopamine Agonist use in Parkinson’s Disease and Hyperprolactinaemia

Original Research Article

Trends in Hepatic Injury Associated with Unintentional Overdose of Paracetamol (Acetaminophen) in Products with and without Opioid